Gut microbe metabolite TMA boosts sugar control by tamping down a pivotal inflammatory switch
A microbial metabolite long tied to cardiovascular risk surfaces here as an unexpected ally against metabolic inflammation, showing how gut–host signaling can reset glucose regulation by hitting a single immune kinase.
Study: Inhibition of IRAK4 by microbial trimethylamine blunts metabolic inflammation and ameliorates glycemic control (https://www.nature.com/articles/s42255-025-01413-8). Image Credit: Ahmet Misirligul / Shutterstock
A new study in Nature Metabolism identifies a gut microbial metabolite that enhances glycemic control and dampens innate-immune–driven inflammation in obese mice by targeting a central kinase in innate immune signaling.
Global Diabetes Burden and Inflammatory Mechanisms
Diabetes, a chronic condition defined by elevated blood sugar, has become a major global public health challenge. The World Health Organization estimates about 529 million people live with diabetes worldwide, with roughly 1.6 million deaths each year attributed to the disease.
Unhealthy lifestyle factors—poor diet and physical inactivity—are closely linked to rising rates of metabolic diseases, including diabetes and obesity.
The gut microbiota—the diverse community of microbes in the digestive tract—plays a crucial role in sustaining low-grade, chronic inflammation and insulin resistance, both hallmarks of diabetes. Research indicates that interactions between bacterial lipopolysaccharides (LPS) and dietary fats can trigger this persistent inflammation and insulin resistance by activating toll-like receptor 4 (TLR4), a key component of the innate immune system.
While some signaling molecules involved in gut microbiota–host chemical communication have been identified, the specific microbial metabolites that regulate these processes remain largely unknown.
Trimethylamine (TMA) is among the most abundant metabolites produced by gut bacteria during the metabolism of dietary choline and carnitine. TMA is a precursor to trimethylamine N-oxide (TMAO), a compound with well-established cardiovascular risks. There is also evidence linking TMA to insulin resistance.
Related Stories
- Blood sugar migration to saliva fuels cavity development in type 2 diabetes patients
- Dash diet cuts diabetes complications by targeting blood pressure, kidney health, and inflammation
- Chronic drinking weakens the blood-brain barrier through the gut
In light of TMA and related metabolites’ possible involvement in cardiometabolic disease, the current study sought to uncover how TMA might mechanistically relate to high-fat-diet–induced glucose intolerance, insulin resistance, and obesity-related metabolic dysfunction.
Experimental Approach to TMA–IRAK4 Interactions
The researchers used mice fed a high-fat diet with either low or high choline content, plus control animals on standard chow, to induce obesity and glucose intolerance and to assess how choline-driven TMA production influences outcomes.
They found that microbial TMA attenuated high-fat-diet–induced low-grade inflammation and insulin resistance by inhibiting interleukin-1 receptor-associated kinase 4 (IRAK4), a key kinase in the toll-like receptor (TLR) pathway that detects danger signals from pathogens.
Genetic silencing and chemical inhibition of IRAK4 produced similar metabolic and immune improvements in high-fat–fed mice, reinforcing the idea that TMA and its target kinase play important roles in immunometabolic regulation.
Additionally, a single TMA dose markedly improved survival in mice subjected to lipopolysaccharide (LPS)–induced septic shock.
Choline Intake, TMA Production, and Immune Modulation
Comparing mice on low- and high-choline, high-fat diets showed that choline supplementation reduced high-fat–induced inflammation. Further analysis revealed a roughly 20-fold rise in circulating TMA levels in mice on a high-choline diet versus those on a low-choline diet, suggesting that gut microbes convert dietary choline into TMA more efficiently when choline intake is higher.
These findings imply that TMA produced through microbial metabolism of dietary choline may mediate the metabolic and immune benefits associated with choline supplementation. In other words, TMA can act as a signaling molecule that engages the TLR pathway to improve glycemic control and dampen host inflammation.
Context-Dependent Roles of TMA and TMAO
In the liver, TMA is oxidized to TMAO, a known cardiovascular risk factor. Yet TMAO has also shown potential benefits in other contexts, such as reducing blood–brain barrier permeability under certain conditions. Conversely, TMA can disrupt the blood–brain barrier. Overall, current evidence suggests that TMAO’s harm may require underlying pathological conditions to become evident.
Some previous studies have reported that choline-rich diets can worsen glucose tolerance and pancreatic beta-cell function in mice by increasing TMAO levels, which contrasts with the current study’s findings. Taken together, this literature hints that TMA and TMAO may have opposing, context- and mechanism-dependent roles.
Mechanistic Insights Into TMA’s Independent Pathway
In the liver, the enzyme flavin-containing monooxygenase 3 (FMO3) converts TMA to TMAO. Inactivating FMO3, thereby increasing TMA relative to TMAO, has been associated with several metabolic benefits. These data suggest that TMA’s benefits cannot be fully explained by lowering TMAO alone, indicating a distinct mechanism for TMA.
Indeed, the current study shows that TMA binds to and inhibits IRAK4, a mechanism not shared by TMAO, underscoring an independent pathway for TMA’s effects.
Implications for Dietary Strategies and Future Trials
Overall, these findings lay a strong groundwork for future clinical trials to explore anti-diabetic effects and improved obesity-related metabolic dysfunction through dietary approaches that aim to boost TMA bioavailability, while noting that human evidence remains limited to in vitro studies at this stage.
Journal reference:
Chilloux J. 2025. Inhibition of IRAK4 by microbial trimethylamine blunts metabolic inflammation and ameliorates glycemic control. Nature Metabolism. DOI: 10.1038/s42255-025-01413-8, https://www.nature.com/articles/s42255-025-01413-8
